Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Asset disposition
Appointed CFO
Quarterly results
Appointed director
CC transcript
CELGENE CORP (CELG) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/14/2018 BW Celgene Corporation to Webcast at Upcoming Investor Conferences and Events
05/04/2018 BW Celgene Reports First Quarter 2018 Operating and Financial Results
04/09/2018 BW Celgene Corporation to Announce First Quarter 2018 Results on May 04, 2018
02/27/2018 BW Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis
02/01/2018 BW Celgene Corporation to Webcast at Upcoming Investor Conferences
01/25/2018 BW Celgene Reports Fourth Quarter and Full-Year 2017 Operating and Financial Results
01/08/2018 BW Celgene Corporation Announces Preliminary 2017 Unaudited Results and 2018 Financial Guidance
01/03/2018 BW Celgene Corporation to Announce Fourth Quarter and Full-Year 2017 Results on January 25, 2018
01/02/2018 BW Celgene Corporation to Present at the 36th Annual J.P. Morgan Healthcare Conference
10/31/2017 BW Celgene Announces Offering of Senior Unsecured Notes
10/28/2017 BW Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS ?? ACTRIMS Meeting
10/26/2017 BW Celgene Reports Third Quarter 2017 Operating and Financial Results
10/02/2017 BW Celgene Corporation to Announce Third Quarter 2017 Results on October 26, 2017; Will Host an Investor Webcast Event from the MSParis2017–7th Joint ECTRIMS – ACTRIMS Meeting on October 28, 2017
07/27/2017 BW Celgene Reports Second Quarter 2017 Operating and Financial Results
07/05/2017 BW Celgene Corporation to Announce Second Quarter 2017 Results on July 27, 2017
04/27/2017 BW Celgene Reports First Quarter 2017 Operating and Financial Results
04/03/2017 BW Celgene Corporation to Announce First Quarter 2017 Results on April 27, 2017
02/03/2017 BW Celgene Corporation to Webcast at Upcoming Investor Conference
08/18/2011 BW Celgene Announces Additional $2 Billion Share Repurchase Authorization
06/06/2011 BW Phase II Study Evaluating Clinical Benefits of ABRAXANE® Plus Gemcitabine and Bevacizumab as First-Line Treatment in Patients with Metastatic Breast Cancer Presented at ASCO
06/06/2011 BW Two Clinical Studies Evaluating Benefits of ABRAXANE® Combinations in Patients with Unresectable Melanoma Presented at ASCO
06/05/2011 BW Phase II Study Evaluates Clinical Benefit of REVLIMID® in Combination Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (MCRPC)
06/04/2011 BW Final Phase III Data from Study CA031 of ABRAXANE® in Combination with Carboplatin in Patients with Non-Small Cell Lung Cancer Presented at ASCO
04/28/2011 BW Celgene Reports Record First Quarter 2011 Operating and Financial Results
04/27/2011 BW Celgene Corporation to Present at Two Upcoming Investor Conferences
04/13/2011 BW Celgene Corporation to Announce First Quarter 2011 Results on April 28, 2011
03/10/2011 BW Celgene Corporation to Present at Barclays Capital 2011 Global Healthcare Conference
03/03/2011 BW Celgene Corporation to Present at the Cowen and Company 31st Annual Health Care Conference
02/28/2011 BW FDA Grants Priority Review For ISTODAX® sNDA For Treatment of Progressive or Relapsed PTCL
02/24/2011 BW Celgene Corporation to Present at the Citi 2011 Global Health Care Conference
02/16/2011 BW Vidaza® Receives Positive Final Appraisal Determination from National Institute for Health and Clinical Excellence (NICE) for Use in the National Health Service (NHS) in England and Wales
02/16/2011 BW Celgene Elects Michael A. Friedman, MD to Board of Directors
02/16/2011 BW Celgene Announces Additional $1 Billion Share Repurchase Program
12/13/2010 BW Celgene Corporation to Present at 2010 Deutsche Bank BioFEST
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy